Cogstate

Clinical trials in patients with rare epilepsy disorders present significant challenges for research teams, including patient identification, site selection, and precise measurement needs. Join Dr. Pam Ventola, Cogstate CSO and Yale Associate Professor, as she provides details to help your team: ▪️ Collect data across large geographic areas ▪️ Approach locations that may not have specialized raters ▪️ Select appropriate cognitive and behavioral endpoints ▪️ Consider approaches to determine MCID 📅 October 3, 2024 | 11am EST ➡️ Register to attend: https://lnkd.in/eHHCMvhn

Lessons from the TRAILBLAZER-ALZ-2 Rater Performance Central Monitoring Program > Data shared in a poster co-authored by Cogstate highlight learnings from a rater performance monitoring program used in the TRAILBLAZER-ALZ 2 Randomized Clinical Trial of Donanemab in Early Symptomatic Alzheimer Disease. Rater performance was analyzed across four outcome measures that were part of the study and are frequently leveraged in AD clinical trials: ADAS-Cog 13, ADCS-ADL, CDR, and MMSE. See the findings and the poster in this article (click link or image below)!

Making decisions about dosing, mechanism of action, and length of effect in sleep medicine can all be better informed when using cognitive assessments.  In this short whitepaper, Professor Paul Maruff, Chief Innovation Officer at Cogstate, uses case examples from clinical trials we’ve supported to explore insights and methodologies that can help clinical trial teams improve decision-making in this area. Find methodologies to bolster your safety and efficacy decisions in sleep-related trials: https://lnkd.in/ecNzqAFG

🌱🌿 Some of the proud “plant parents” here at Cogstate! One of the many perks of a virtual-first policy is the ability to make our workspaces as unique as we are, including an abundance of plants (if we so choose). Whether we display bouquets from our kids, chill with a poisonous cactus, or take a coffee break in a thriving outdoor space, we’re basking in our remote work life! Without fail, ‘remote working’ questions in our Cogstate team member surveys are one of the highest scoring factors. We’ve leaned into this model and are loving the results--happy employees and continued positive business outputs.

Cognitive measurement can be used to understand effects of medicines used to optimize sleep or wakefulness. In this short video, Cogstate CIO, Paul Maruff, answers questions about this topic, including: •Can the sedative effects of drugs like benzodiazepines observed in healthy young adults help estimate their impact on older adults? •How do these sedative effects translate across different patient populations? •Is the fatigue reported by people with MS similar to that experienced by individuals with Parkinson’s disease? And can the same wake-promoting drugs be effective in both groups? 📺 Gather his thoughts on YouTube 👉 https://lnkd.in/eg5FWjhf

🧠 📱 Lila is a self-administered memory app that uses virtual assistant and natural language processing technology to mimic face-to-face administration, making cognitive assessment accessible at home with immediate feedback. Lila is based on the well-known, highly-validated Cogstate International Shopping List Test (ISLT). The ISLT has been used extensively in global studies of early Alzheimer's Disease. Check out updates about Lila from our Science Director, Svenja Wacker, and discover how this tool could impact not only clinical trials and healthcare settings, but also empower consumers to track their own cognitive health over time: https://lnkd.in/eeEDesGX

🌎 51,398 people are participating in Alzheimer’s Disease clinical trials worldwide. This statistic and others from a recent report published in the journal Alzheimer's & Dementia highlight the scope of the current AD drug development landscape. Based on an analysis of clinicatrials.gov led by Jeffrey Cummings, this recent report shares trial numbers, therapeutic targets, biomarkers, innovations, recruitment timelines, and an array of information detailing the vital research ongoing in this therapeutic area. Find more statistics here 👉 https://lnkd.in/eHjdXZTQ

A recent paper in the Journal of Prevention of Alzheimer's Disease highlights a secondary analyses from the A4 study. Researchers noted changes in digital cognitive test performance (including the Cogstate CBB) between solanezumab and placebo groups in the preclinical AD trial. "Important work here from the A4 study group, lead by Dr Kate Papp," said Paul Maruff, Cogstate CIO and paper co-author. "The publication shows for the first time that digital cognitive assessments, including those from the Cogstate Brief Battery are sensitive to amyloid related cognitive decline over 240 weeks in adults enrolled in the A4 clinical trial. As was observed for the PACC, there was no benefit of the study drug in adults with preclinical AD."  The cognitive data collapsed across treatment and placebo groups provides important information for understanding disease progression and cognitive decline in clinical trials of adults with preclinical AD. Read the paper here - https://lnkd.in/eXVY-2ux

It's showtime. #AAIC24 The Cogstate Crew is in the middle of all the action at the Alzheimer's Association® International Conference in Philadelphia this week. If you are in town, swing by Booth 1407 for a chat! #AlzheimersDisease #Alzheimers

#AAIC24 starts next week! We invite conference participants to stop by Cogstate’s booth to demo a self-adminstered cognitive testing experience on your smartphone or tablet device. Learn more about scalable and sensitive cognitive testing solutions for your trials. See Cogstate’s 22 AAIC scientific presentations > https://lnkd.in/e6aytt7f